MRNA-based platform for preventing and treating <i>Staphylococcus aureus</i> by targeted staphylococcal enterotoxin B.

ABSTRACT: Staphylococcus aureus (S. aureus) possesses numerous virulence factors, with the increasing prevalence of drug-resistant strains heightening the threat posed by this pathogen. Staphylococcal enterotoxin B (SEB), a highly conserved toxin secreted by S. aureus, is also recognized as a potential bioweapon with super-antigenic activity. SEB represents a promising target in efforts to combat infections caused by S. aureus. We developed mRNA-based vaccine and antibody targeting SEB for both prophylactic and therapeutic purposes in varying S. aureus infection conditions. The mSEB mRNA vaccine (10 μg per mouse) induces more robust and persistent immune responses, including higher antibody titers and specific cellular immune responses, compared to immunization wit

SUBMITTER: Luo F 

PROVIDER: S-EPMC11617584 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature